$20.35
0.97% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
NL00150005Y4
Symbol
PHVS
Sector
Industry

Pharvaris NV Stock price

$20.35
-0.47 2.26% 1M
-1.75 7.92% 6M
-7.70 27.45% YTD
+3.95 24.09% 1Y
+4.45 27.99% 3Y
+0.35 1.75% 5Y
+0.35 1.75% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.20 0.97%
ISIN
NL00150005Y4
Symbol
PHVS
Sector
Industry

Key metrics

Market capitalization $1.10b
Enterprise Value $758.58m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.33
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-138.61m
Free Cash Flow (TTM) Free Cash Flow $-118.76m
Cash position $340.61m
EPS (TTM) EPS $-2.68
P/E forward negative
Short interest 0.33%
Show more

Is Pharvaris NV a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Pharvaris NV Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Pharvaris NV forecast:

7x Buy
88%
1x Sell
13%

Analyst Opinions

8 Analysts have issued a Pharvaris NV forecast:

Buy
88%
Sell
13%

Financial data from Pharvaris NV

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.26 0.26
4% 4%
-
-0.26 -0.26
4% 4%
-
- Selling and Administrative Expenses 45 45
41% 41%
-
- Research and Development Expense 93 93
39% 39%
-
-138 -138
39% 39%
-
- Depreciation and Amortization 0.26 0.26
4% 4%
-
EBIT (Operating Income) EBIT -139 -139
39% 39%
-
Net Profit -143 -143
26% 26%
-

In millions USD.

Don't miss a Thing! We will send you all news about Pharvaris NV directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pharvaris NV Stock News

Neutral
GlobeNewsWire
2 days ago
ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced financial results for the third quarter ended September 30, 2024, and highlighted recent business updates.
Neutral
GlobeNewsWire
4 days ago
ZUG, Switzerland, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced that its management will participate in the Inaugural Guggenheim Securities Healthcare Innovation Conference, taking place from November 11-13, 2024...
Neutral
GlobeNewsWire
about one month ago
ZUG, Switzerland, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of multiple abstracts at several upcoming scientific meetings. Presentation details are as follows:
More Pharvaris NV News

Company Profile

Pharvaris NV is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Hans G. C. P. Schikan and Anne Lesage on September 30, 2015 and is headquartered in Leiden, Netherlands.

Head office Netherlands
CEO Berndt Modig
Employees 82
Founded 2015
Website www.pharvaris.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today